Aimia Inc. (TSX:AIM)
2.820
+0.040 (1.44%)
Apr 8, 2026, 10:30 AM EST
Aimia Revenue
In the year 2025, Aimia had annual revenue of 503.40M CAD with 0.52% growth. Aimia had revenue of 118.50M in the quarter ending December 31, 2025, a decrease of -6.84%.
Revenue
503.40M
Revenue Growth
+0.52%
P/S Ratio
0.48
Revenue / Employee
214.51K
Employees
2,385
Market Cap
247.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 503.40M | 2.60M | 0.52% |
| Dec 31, 2024 | 500.80M | 209.60M | 71.98% |
| Dec 31, 2023 | 291.20M | 289.70M | 19,313.33% |
| Dec 31, 2022 | 1.50M | -11.10M | -88.10% |
| Dec 31, 2021 | 12.60M | -1.70M | -11.89% |
| Dec 31, 2020 | 14.30M | -113.00M | -88.77% |
| Dec 31, 2019 | 127.30M | -39.80M | -23.82% |
| Dec 31, 2018 | 167.10M | -65.00M | -28.01% |
| Dec 31, 2017 | 232.10M | -1.53B | -86.81% |
| Dec 31, 2016 | 1.76B | -701.30M | -28.50% |
| Dec 31, 2015 | 2.46B | -8.20M | -0.33% |
| Dec 31, 2014 | 2.47B | 795.30M | 47.52% |
| Dec 31, 2013 | 1.67B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neo Performance Materials | 656.48M |
| AirBoss of America | 562.44M |
| 5N Plus | 536.19M |
| EcoSynthetix | 28.52M |
| California Nanotechnologies | 4.24M |
| International Parkside Products | 2.82M |
| Graphene Manufacturing Group | 267.39K |
| HydroGraph Clean Power | 85.59K |
Aimia News
- 14 days ago - Aimia Inc (AIMFF) Q4 2025 Earnings Call Highlights: Navigating Challenges and Capitalizing on ... - GuruFocus
- 14 days ago - Q4 2025 Aimia Inc Earnings Call Transcript - GuruFocus
- 15 days ago - AIMIA REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS - Benzinga
- 20 days ago - AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress - International Business Times (Australia)
- 20 days ago - Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
- 21 days ago - AIM ImmunoTech Gains Japanese Patent Approval for Cancer Treatment - GuruFocus
- 23 days ago - AIMIA DECLARES PREFERRED SHARE DIVIDENDS - Benzinga
- 4 weeks ago - Verdict parent company GlobalData moves to Main Market of LSE - Verdict